Rigel Pharmaceuticals IncNASDAQ:RIGL
- LAST PRICE1.4000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.3500/ 10
- Ask / Lots1.4000/ 22
- Open / Previous Close1.4100 / 1.4000
- Day Range
- 52 Week Range
- Volume1,378,269
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RIGL |
|---|---|---|
| 09:32 ET | 11900 | 1.41 |
| 09:34 ET | 47796 | 1.405 |
| 09:36 ET | 80457 | 1.4099 |
| 09:38 ET | 8659 | 1.4 |
| 09:39 ET | 35532 | 1.39 |
| 09:41 ET | 886 | 1.3992 |
| 09:43 ET | 9897 | 1.3898 |
| 09:45 ET | 1701 | 1.39 |
| 09:48 ET | 1700 | 1.385 |
| 09:50 ET | 15496 | 1.385 |
| 09:52 ET | 14600 | 1.375 |
| 09:54 ET | 61588 | 1.38 |
| 09:56 ET | 800 | 1.375 |
| 09:57 ET | 1009 | 1.375 |
| 09:59 ET | 27883 | 1.3799 |
| 10:01 ET | 44600 | 1.3801 |
| 10:03 ET | 13002 | 1.3796 |
| 10:06 ET | 4200 | 1.3796 |
| 10:08 ET | 15200 | 1.375 |
| 10:10 ET | 200 | 1.375 |
| 10:12 ET | 3100 | 1.38 |
| 10:14 ET | 14693 | 1.385 |
| 10:15 ET | 1800 | 1.385 |
| 10:17 ET | 100 | 1.385 |
| 10:19 ET | 970 | 1.39 |
| 10:21 ET | 3600 | 1.39 |
| 10:24 ET | 223 | 1.395 |
| 10:26 ET | 700 | 1.395 |
| 10:28 ET | 3983 | 1.39 |
| 10:30 ET | 6062 | 1.405 |
| 10:32 ET | 4281 | 1.4 |
| 10:33 ET | 3469 | 1.385 |
| 10:35 ET | 658 | 1.39 |
| 10:37 ET | 3728 | 1.395 |
| 10:39 ET | 600 | 1.39 |
| 10:44 ET | 500 | 1.39 |
| 10:46 ET | 1455 | 1.39 |
| 10:48 ET | 2400 | 1.3988 |
| 10:50 ET | 6062 | 1.39 |
| 10:51 ET | 1677 | 1.385 |
| 10:53 ET | 200 | 1.385 |
| 10:55 ET | 600 | 1.385 |
| 10:57 ET | 3800 | 1.38 |
| 11:00 ET | 400 | 1.385 |
| 11:02 ET | 9500 | 1.3801 |
| 11:04 ET | 798 | 1.38 |
| 11:08 ET | 388 | 1.38 |
| 11:09 ET | 500 | 1.38 |
| 11:11 ET | 9006 | 1.385 |
| 11:13 ET | 1356 | 1.38 |
| 11:15 ET | 1117 | 1.385 |
| 11:18 ET | 1000 | 1.3899 |
| 11:20 ET | 1700 | 1.38 |
| 11:22 ET | 708 | 1.38 |
| 11:24 ET | 10100 | 1.38 |
| 11:26 ET | 13759 | 1.375 |
| 11:27 ET | 19295 | 1.37 |
| 11:29 ET | 700 | 1.37 |
| 11:36 ET | 1954 | 1.37 |
| 11:38 ET | 15864 | 1.3599 |
| 11:40 ET | 16345 | 1.3588 |
| 11:42 ET | 27240 | 1.365 |
| 11:44 ET | 300 | 1.36 |
| 11:45 ET | 102 | 1.37 |
| 11:49 ET | 1000 | 1.3609 |
| 11:51 ET | 36768 | 1.36 |
| 11:54 ET | 33578 | 1.345 |
| 11:56 ET | 54995 | 1.3401 |
| 11:58 ET | 3200 | 1.3499 |
| 12:00 ET | 3859 | 1.35 |
| 12:02 ET | 13582 | 1.345 |
| 12:03 ET | 1855 | 1.345 |
| 12:05 ET | 5200 | 1.345 |
| 12:07 ET | 13597 | 1.345 |
| 12:09 ET | 500 | 1.35 |
| 12:12 ET | 8535 | 1.345 |
| 12:16 ET | 1800 | 1.3499 |
| 12:18 ET | 11040 | 1.35 |
| 12:20 ET | 100 | 1.345 |
| 12:21 ET | 200 | 1.345 |
| 12:25 ET | 2100 | 1.3499 |
| 12:27 ET | 11997 | 1.35 |
| 12:30 ET | 300 | 1.36 |
| 12:32 ET | 400 | 1.3591 |
| 12:34 ET | 405 | 1.355 |
| 12:36 ET | 377 | 1.355 |
| 12:38 ET | 2242 | 1.3567 |
| 12:39 ET | 3728 | 1.365 |
| 12:43 ET | 413 | 1.365 |
| 12:48 ET | 602 | 1.365 |
| 12:54 ET | 1135 | 1.365 |
| 01:01 ET | 1352 | 1.3684 |
| 01:10 ET | 450 | 1.3673 |
| 01:12 ET | 100 | 1.3699 |
| 01:14 ET | 15635 | 1.3629 |
| 01:15 ET | 1188 | 1.365 |
| 01:21 ET | 400 | 1.365 |
| 01:24 ET | 300 | 1.365 |
| 01:28 ET | 11717 | 1.35 |
| 01:30 ET | 300 | 1.355 |
| 01:32 ET | 100 | 1.355 |
| 01:35 ET | 250 | 1.35 |
| 01:37 ET | 9464 | 1.36 |
| 01:39 ET | 5100 | 1.35 |
| 01:44 ET | 1467 | 1.3518 |
| 01:46 ET | 11732 | 1.3642 |
| 01:53 ET | 4374 | 1.365 |
| 01:55 ET | 600 | 1.37 |
| 02:00 ET | 4008 | 1.36 |
| 02:06 ET | 100 | 1.3611 |
| 02:08 ET | 2702 | 1.365 |
| 02:09 ET | 1200 | 1.365 |
| 02:11 ET | 2600 | 1.36 |
| 02:18 ET | 4066 | 1.37 |
| 02:20 ET | 100 | 1.365 |
| 02:22 ET | 2000 | 1.3609 |
| 02:24 ET | 100 | 1.365 |
| 02:27 ET | 2233 | 1.365 |
| 02:29 ET | 1000 | 1.365 |
| 02:31 ET | 14785 | 1.38 |
| 02:33 ET | 3444 | 1.385 |
| 02:36 ET | 200 | 1.385 |
| 02:38 ET | 10400 | 1.385 |
| 02:40 ET | 1383 | 1.385 |
| 02:42 ET | 6431 | 1.375 |
| 02:44 ET | 9999 | 1.3803 |
| 02:45 ET | 100 | 1.38 |
| 02:47 ET | 6451 | 1.3801 |
| 02:49 ET | 4400 | 1.385 |
| 02:51 ET | 1400 | 1.38 |
| 02:54 ET | 1100 | 1.38 |
| 02:58 ET | 1200 | 1.38 |
| 03:00 ET | 2282 | 1.385 |
| 03:02 ET | 870 | 1.38 |
| 03:03 ET | 12617 | 1.39 |
| 03:05 ET | 6300 | 1.385 |
| 03:09 ET | 14122 | 1.3805 |
| 03:12 ET | 7722 | 1.38 |
| 03:14 ET | 4291 | 1.38 |
| 03:16 ET | 11209 | 1.39 |
| 03:18 ET | 7603 | 1.39 |
| 03:20 ET | 27037 | 1.385 |
| 03:21 ET | 4000 | 1.38 |
| 03:23 ET | 4843 | 1.375 |
| 03:25 ET | 9581 | 1.375 |
| 03:27 ET | 2081 | 1.38 |
| 03:30 ET | 1552 | 1.375 |
| 03:32 ET | 3341 | 1.38 |
| 03:34 ET | 8947 | 1.385 |
| 03:36 ET | 1200 | 1.38 |
| 03:38 ET | 800 | 1.38 |
| 03:39 ET | 5750 | 1.38 |
| 03:41 ET | 22119 | 1.385 |
| 03:43 ET | 8620 | 1.385 |
| 03:45 ET | 5077 | 1.385 |
| 03:48 ET | 2350 | 1.385 |
| 03:50 ET | 5816 | 1.39 |
| 03:52 ET | 3538 | 1.39 |
| 03:54 ET | 12785 | 1.39 |
| 03:56 ET | 25072 | 1.39 |
| 03:57 ET | 30992 | 1.39 |
| 03:59 ET | 16766 | 1.4 |
Yesterday
Rigel Announces Poster Presentation at the Upcoming 2023 American Society of Clinical Oncology Annual Meeting, from 8:05AM ET on Thursday Jun 01, 2023 by PR Newswire
8:05AM ET on Thursday Jun 01, 2023 by PR Newswire
May 31, 2023
Rigel to Present at the Jefferies 2023 Global Healthcare Conference, from 8:05AM ET on Wednesday May 31, 2023 by PR Newswire
8:05AM ET on Wednesday May 31, 2023 by PR Newswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Rigel Pharmaceuticals Inc | 243.1M | -5.5x | --- |
Kamada Ltd | 211.6M | -93.1x | --- |
Poseida Therapeutics Inc | 197.8M | -4.0x | --- |
Sangamo Therapeutics Inc | 190.7M | -1.4x | --- |
Selecta Biosciences Inc | 191.8M | -13.3x | --- |
Xeris Biopharma Holdings Inc | 359.8M | -4.9x | --- |
Company Information
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in discovering, developing and providing therapies that improve the lives of patients with hematologic disorders and cancer. The Company's lead product, TAVALISSE (fostamatinib disodium hexahydrate) tablets, the spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Its product also includes REZLIDHIA (olutasidenib) capsules, which are for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. Its other clinical programs include its interleukin receptor-associated kinase (IRAK) inhibitor program and a receptor-interacting serine/threonine-protein kinase (RIPK1) inhibitor program in clinical development. In addition, it has product candidates in clinical development with partners BerGenBio ASA (BerGenBio) and Daiichi Sankyo (Daiichi).
Contact Information
- Headquarters
- 611 GATEWAY BOULEVARD, SUITE 900SOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- 650-624-1100
- Fax
- 650-624-1101
Executives
- Independent Chairman of the Board
- Gregg Lapointe
- President, Chief Executive Officer, Director
- Raul Rodriguez
- Chief Financial Officer, Executive Vice President
- Dean Schorno
- Executive Vice President, General Counsel, Company Secretary
- Raymond Furey
- Executive Vice President, Chief Commercial Officer
- David Santos
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $243.1M |
|---|---|
Revenue (TTM) | $129.6M |
Shares Outstanding | 173.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.72 |
EPS | $-0.26 |
Book Value | $-0.08 |
P/E Ratio | -5.5x |
Price/Sales (TTM) | 1.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -32.42% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
